摘要
目的:探讨阿帕替尼联合卡瑞利珠单抗治疗晚期三阴性乳腺癌(TNBC)患者的效果及其对细胞免疫、远期预后的影响。方法:采用随机数字表法将我院于2019年6月—2022年2月收治的82例晚期TNBC患者分为两组,每组41例。单一组给予卡瑞利珠单抗治疗,联合组加用阿帕替尼治疗,比较两组临床疗效、细胞免疫功能、远期预后以及不良反应发生率。结果:联合组总有效率高于单一组(P<0.05);两组CD3^(+)、CD4^(+)和NK细胞高于治疗前,CD8^(+)低于治疗前,且联合组改变幅度大于单一组(P<0.05);两组总生存时间、不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿帕替尼联合卡瑞利珠单抗治疗晚期TNBC患者疗效突出,能够显著改善患者细胞免疫功能,抑制肿瘤进展,改善远期预后,且不增加不良反应发生率,安全可控。
Objective:To investigate the efect of apatinib combined with carrelizumab in the treatment of patients with advanced triple negative breast cancer(TNBC)and its efect on cellular immunity and long-term prognosis.Methods:A total of 82 patients with advanced TNBC admitted to our hospital from June 2019 to February 2022 were divided into two groups by random number table method,with 41 cases in each group.The single group was treated with carrelizumab,and the combined group was treated with apatinib.The clinical efcacy,cellular immune function,long-term prognosis and incidence of adverse reactions were compared between the two groups.Results:The total efective rate of the combined group was higher than that of the single group(P<0.05).CD3^(+),CD4^(+)and NK cells in the two groups were higher than those before treatment,CD8^(+)was lower than that before treatment,and the change in the combined group was greater than that in the single group(P<0.05).There was no signifcant diference in total survival time and incidence of adverse reactions between the two groups(P>0.05).Conclusion:Apatinib combined with carrelizumab is efective in the treatment of advanced TNBC patients,which can signifcantly improve the cellular immune function,inhibit tumor progression,improve long-term prognosis,and does not increase the incidence of adverse reactions.It is safe and controllable.
作者
吴星星
刘佳
魏洁
WU Xingxing;LIU Jia;WEI Jie(Department of Oncology,the 989th Hospital of Joint Logistic Support Force,Luoyang 471000,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2024年第4期695-698,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
阿帕替尼
卡瑞利珠
三阴性乳腺癌
细胞免疫功能
Apatinib
Carrelizumab
Triple negative breast cancer
Cellular immune function
